Senator Daines Questions RFK Jr. on Abortion Pill Safety and Mail Access

Deregulation of Chemical Abortion Drugs

• ⚠️ The FDA has progressively removed safeguards for mifepristone since its 2000 approval, eliminating requirements for doctor's prescriptions, follow-up visits, and adverse event reporting.
• 📬 The drug is now permitted to be sent through the mail, a practice questioned due to safety concerns.

Adverse Event Study Findings

• 📊 A recent study analyzing 865,000 insurance claims found that nearly 11% of women experienced a serious adverse event within 45 days of taking mifepristone.
• 📈 This rate is significantly higher, approximately 22 times greater, than the FDA's previous estimates of less than 0.5%.
• 🗣️ Medical professionals suggest that even this study might underrepresent the true scale of the problem.

Safety Concerns and Misinformation

• 🤥 The claim that mifepristone is as safe as Tylenol is described as a misleading and harmful lie.
• 💔 Tragically, two women died last year due to chemical abortion pills accessed without appropriate medical oversight, a situation enabled by the FDA.

FDA Review and Data Analysis

• 🔍 Senator Daines acknowledges the FDA commissioner's review of new data on mifepristone safety.
• 🗣️ Discussions with FDA leadership indicate that studies on the safety data are progressing and ongoing.
• 🤝 There is an encouragement for continued conversations to ensure the FDA studies the exposed data and considers appropriate actions.

Telemedicine and COVID-Era Allowances

• ❓ A question is raised about repealing the COVID-era telemedicine allowance for chemical abortion drugs.
• 🏥 The request is to restore the requirement for an in-person doctor visit for these medications, aligning with the rollback of other COVID-era emergency measures.
• ↩️ The Secretary states he needs to get back on this issue, as the White House position is not yet clear.